Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medtronic, a medical technology company, has announced the US market launch of the Talent thoracic stent graft on the Xcelerant delivery system, which reportedly makes minimally invasive treatment of thoracic aortic aneurysms easier to perform.
Subscribe to our email newsletter
Recently approved by the FDA, the Talent thoracic stent graft with the new delivery system is now available to physicians across the US. The Talent thoracic stent graft expands the applicability of thoracic endovascular aortic repair to more patients with thoracic aortic aneurysms.
According to the company, the unique features of the Xcelerant delivery system and the Talent thoracic stent graft provide meaningful benefits to both physician and patient: a wide range of sizes so more patients can be treated; improved trackability and controlled deployment for easier and more accurate stent graft placement; and high radial force as shown in competitive bench testing.
Tony Semedo, vice president and general manager of endovascular innovations, part of the CardioVascular business at Medtronic, said: “The Xcelerant delivery system unlocks the full potential of the Talent thoracic stent graft by combining unique features that are unavailable in the current alternatives.”